What is this?
cGMP release testing applies verified compendial methods or validated custom methods to drug substances, drug products, tablets, capsules, excipients, and other materials to support batch disposition and CoA issuance.
Start with the regulated decision
Use validated or verified methods to support batch disposition, CoA issuance, stability, and regulatory documentation.
For cGMP work, method choice has to follow the quality attribute, sample matrix, method status, documentation need, and regulatory decision. The testing plan should connect method development, validation, method transfer, release testing, CoA support, and documentation requirements rather than treating each instrument run as an isolated activity.
Overview of cGMP Release Testing Services
When is it used?
Use release testing when a lot must be dispositioned for clinical supply, commercial supply, stability, incoming material qualification, investigation closure, or regulatory submission support.
What are limitations?
Release testing cannot rescue an unsuitable method. The method, specification, reference standards, sample plan, system suitability, deviations, OOS handling, and CoA wording must be aligned before testing.
What sample amounts are needed?
Amounts depend on the test panel, monograph, destructive tests, replicate needs, retains, and retesting policy. Enough material must be provided for the planned specification and any confirmed repeats.
What techniques compete with it?
Competing or orthogonal methods include XRPD, Raman, FTIR, NMR, HPLC/GC, LC/MS, TGA/DSC, KF, particle-size analysis, microscopy, PLM, SEM/EDX, ICP-MS, and compendial tests depending on the quality attribute.
What does FDA care about?
FDA cares about method status, data integrity, sample traceability, standards, calculations, analyst review, deviation/OOS handling, CoA accuracy, and lifecycle control.
What are common mistakes?
Common mistakes include using exploratory data as release evidence, validating the wrong matrix, ignoring sample preparation, under-documenting controls, relying on one technique when orthogonal evidence is needed, or failing to define the decision before testing.
What is Triclinic's experience with this technique
Triclinic supports real-world cGMP release testing by coordinating controlled analytical methods, documentation, review, and reporting around the quality decision the data must support. Applications include API, excipient, raw-material, intermediate, and finished-material testing; stability pulls; method transfer or verification; CoA support; and investigations when release data, specifications, or material history require analytical interpretation.
What changes when the work is cGMP?
Exploratory data can help choose a method, but release or filing-support data require controlled execution. The method must be suitable for the matrix, the quality attribute must be defined, reference standards and controls must be appropriate, and the report or CoA must say only what the data support.
| cGMP concern | Why it matters | Practical control |
|---|---|---|
| Method status | Exploratory, verified compendial, validated custom, and transferred methods have different evidence requirements. | Define status before testing and document any development, verification, validation, or transfer work. |
| Sample matrix | Specificity can fail in real drug product, excipient, talc, low-dose, or complex solid mixtures. | Use representative material, placebo/matrix controls, spike studies, or orthogonal methods where needed. |
| Data integrity | Release or stability results must survive QA review, audit, and regulatory scrutiny. | Use controlled records, system suitability, analyst review, deviations/OOS process, and traceable calculations. |
Specific instruments and capabilities for cGMP Release Testing Services
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this cGMP service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| HPLC / UPLC platforms | Agilent 1100 and Agilent 1260 Infinity II systems with Chromeleon 7.2 software; diode-array, refractive-index, and light-scattering detectors | Assay, impurity profiling, additive analysis, extractables/leachables, purity, potency, method development, transfer, and validation. |
| Dissolution testing | VanKel VF750D dissolution platform with UV/VIS or HPLC detection | Dissolution profiles, in vitro release support, bioavailability-relevant release comparisons, and USP <711>-style method support. |
| Disintegration testing | Testerion DT2 | Disintegration behavior of tablets and hard-gelatin capsules under standardized conditions. |
| Karl Fischer water determination | Mettler Toledo V20 and C20 systems | Volumetric and coulometric KF water-content analysis for solids, liquids, and formulations. |
| Particle-size analysis | Malvern Mastersizer 3000 v.3.70 with Malvern Access Configurator v.2.20 | Dry and wet PSD method development, validation, transfer, verification, and release-testing support. |
| Powder X-ray diffraction | Rigaku SmartLab diffractometers with Cu source; 1D/2D capability; reflection and transmission geometries; HyPix-3000 photon-counting detector on the 2D system | Phase ID, quantitative phase analysis, crystallinity, solid-form control, and cGMP/non-GMP XRPD method support. |
cGMP Method Readiness Before Batch Release Testing
This example uses release testing as a readiness decision rather than only a lab execution step. A cGMP release-testing program may involve CoA issuance, finished-product and bulk-lot testing, reference standard qualification, method development, method validation, method transfer, detection-limit testing, linearity, precision, repeatability, accuracy, and quantitation-limit testing. The point of the case is to confirm method status before the sample is treated as a batch-release submission.
| Release-readiness question | Why it matters |
|---|---|
| Is the method exploratory, verified, validated, or transferred? | The method status determines whether the result can support release, stability, filing support, or investigation closure. |
| Are standards, controls, and sample matrix appropriate? | System suitability and specificity must be defensible for the actual product or material being tested. |
| Are acceptance criteria and report language defined? | A CoA or release report should not imply more than the validated or verified method can support. |
| Are deviations and data-integrity requirements controlled? | Regulated release testing requires audit-ready documentation, traceability, and deviation handling. |
Technical Resources and Publications
These examples cite Triclinic source documents, regulatory guidances, or literature relevant to this cGMP service. Download buttons are positioned at the bottom-left of each example.
ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: These harmonized guidances describe validation and development principles for analytical procedures used to assess drug-substance and drug-product quality. They anchor expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence in cGMP work.
Related cGMP services
NMR
Use cGMP NMR for identity, purity, qNMR, reference-material verification, method development, validation, and release testing.
View serviceXRPD
Use cGMP XRPD for solid-form identification, polymorph or phase quantitation, crystallinity, method validation, release, and stability support.
View serviceParticle Size Analysis
Develop, validate, verify, and transfer wet or dry particle-size methods for release specifications and quality decisions.
View serviceThermal Analysis (TGA/DSC)
Use cGMP DSC and TGA to evaluate melting, desolvation, dehydration, glass transitions, degradation, and thermal material control.
View serviceRaman / FTIR
Use cGMP Raman and FTIR for raw-material ID, solid-form differentiation, mapping, contaminant ID, and validated spectroscopic methods.
View serviceMorphology
Use cGMP microscopy and particle morphology evidence for identification, particle shape, foreign-material work, and regulated investigations.
View serviceCommon questions
When should cGMP Release Testing Services be run under cGMP?
Run the work under cGMP when the result will support release, stability, regulatory documentation, method validation or transfer, CoA issuance, or a quality investigation rather than exploratory screening only.
How much material should be submitted?
Material requirements depend on method, matrix, replicate design, standards, destructive testing, retain needs, and whether method development, validation, transfer, or release testing is required. Confirm exact amounts before shipment.
Can Triclinic help choose the method?
Yes. The project should be scoped from the quality attribute, sample matrix, method status, and regulatory decision before selecting a technique or validation plan.
What makes the result defensible?
Defensible cGMP results require appropriate method status, sample traceability, reference standards, controls, system suitability, analyst training, data review, and clear reporting of limitations.
Do you develop, validate, and transfer methods?
Yes. Triclinic develops, validates, verifies, and transfers methods used for cGMP release testing when an existing method is not yet suitable for the sample, matrix, specification, or reporting decision. Method work can include suitability review, development or optimization, validation or verification, transfer readiness, system suitability, sample controls, acceptance criteria, reporting language, and QA documentation needed for CoA or release-support packages.
Can Triclinic support recurring release-testing programs?
Yes. Recurring programs should define forecasted volume, sample and standard supply, method ownership, specifications, turnaround expectations, quality agreements, deviation and OOS responsibilities, reporting, retain requirements, and change control.
Discuss cGMP testing requirements
Send the sample type, intended use of the data, method or monograph if available, specification, matrix, timeline, and whether the work is exploratory, cGMP, validation, transfer, stability, release, or investigation support.